Company Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.
The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program.
The company was incorporated in 2016 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Taylor Schreiber |
Contact Details
Address: 500 West 5th Street, Suite 1200 Austin, Texas 78701 United States | |
| Phone | 512 900 4690 |
| Website | shattucklabs.com |
Stock Details
| Ticker Symbol | STTK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1680367 |
| CUSIP Number | 82024L103 |
| ISIN Number | US82024L1035 |
| Employer ID | 81-2575858 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Andrew R. Neill M.B.A. | Chief Financial Officer |
| Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer |
| Brad Huckabee | Vice President of Accounting and SEC reporting |
| Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer |
| Kelli Collin M.S. | Senior Vice President of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2026 | SCHEDULE 13G | Filing |
| Jun 15, 2026 | SCHEDULE 13D/A | Filing |
| Jun 11, 2026 | SCHEDULE 13D/A | Filing |
| Jun 11, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 424B5 | Filing |
| Jun 9, 2026 | 424B5 | Filing |
| Jun 9, 2026 | 8-K | Current Report |
| Jun 2, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | 144 | Filing |